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Abstract
Background: Hepatitis B virus (HBV) infection causes acute and chronic liver disease, ultimately leading to the
development of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Phospholipase A2 group IIA (PLA2G2A)
plays important roles in the development and progression of many tumors. Thus far, there have been no reports on
the association between HBV and PLA2G2A. The present study investigated the effect of HBV infection on PLA2G2A
expression and its application in the diagnosis of HBV-related diseases.
Methods: Serum levels of PLA2G2A in 308 HBV-infected patients and 185 healthy controls were measured using
an enzyme-linked immunosorbent assay (ELISA). The difference in serum levels of PLA2G2A was analyzed among
chronic hepatitis B (CHB), LC, and HCC patients. PLA2G2A mRNA and protein expression in HepG2 and HepG2.2.15
cells carrying the integrated HBV genome were measured using reverse transcription polymerase chain reaction
(RT-PCR) and western blot assays. The HBV infectious clone pHBV1.3, the control plasmid pBlue-ks and PLA2G2A
gene promoter were transfected into HepG2 and HepG2.2.15 cells. After transfection, the luciferase activity was
measured in the cells. PLA2G2A mRNA and protein expression levels were examined using RT-PCR and western
blot assays.
Results: The serum levels of PLA2G2A were 258.3 ± 20.3ng/dl in the healthy controls and 329.0 ± 22.5ng/dl,
385.4 ± 29.3ng/dl and 459.2 ± 38.6ng/dl in the CHB, LC, and HCC patients, respectively. Statistical analyses revealed
significantly higher serum levels of PLA2G2A in CHB, LC, and HCC patients than in the healthy controls (P < 0.05),
and PLA2G2A levels were elevated in the order of HCC > LC > CHB group. High serum PLA2G2A levels in HCC
patients were associated with a lower prevalence of lymph node metastasis and a lower TNM stage. HepG2.2.15
cells carrying the HBV genome expressed higher levels of PLA2G2A mRNA and protein than the HepG2 cells. In
addition, HBV triggered PLA2G2A promoter activity and enhanced PLA2G2A mRNA and protein expression
compared to the empty vector pBlue-ks.
Conclusion: HBV can upregulate the expression of PLA2G2A, and serum levels of PLA2G2A are associated with the
progression of HBV-related diseases.
Keywords: Hepatitis B virus, Phospholipase A2 group IIA, Chronic hepatitis B, Liver cirrhosis, Hepatocellular
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Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths. Hepatitis B virus (HBV)
infection is a major factor for HCC development.
Chronic hepatitis B (CHB) may lead to the development
of liver cirrhosis (LC) and HCC. It is estimated that the
risk of developing HCC is 200 times higher in chronic
HBV-infected patients than in the general population
without HBV infection [1–4]. However, the carcinogenic
mechanism of HBV-related HCC is still poorly under-
stood. It is generally considered that HBV infection is
noncytopathic [5, 6]. Instead, considerable evidence has
shown an immune and inflammatory contribution to
liver dysfunction, HBV infection activates a number of
cellular genes including interleukin 27 (IL-27), IL-29,
IL-8 and cyclooxygenase 2 [7–9]. In a previous research,
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we screened differentially expressed genes in HepG2.2.15
cells and HepG2 cells using gene chips [10]. Phospholip-
ase A2 group IIA (PLA2G2A) was identified as a highly
expressed gene in HepG2.2.15 cells (data not shown).
PLA2G2A is a secreted protein that is a member of
the phospholipase A2 family. PLA2G2A is widely
present in various mammalian tissues, such as the lung,
thymus, liver, kidney, and prostate [11, 12]. PLA2G2A is
closely associated with the inflammatory and immune
response in the body [12, 13], and it also plays an
important role in the development and progression of
tumors [14, 15]. The aim of the present study was to
investigate the effect of HBV infection on PLA2G2A ex-
pression, its application in the diagnosis of HBV-related
diseases, and the underlying molecular mechanism. The
results will provide new insights as to the pathogenesis
of HBV and for the diagnosis of HBV-related diseases.
Methods
Study subjects
In total, 308 patients clinically diagnosed with chronic
HBV infection were recruited. According to the clinical,
biochemical, serological, histopathological, abdominal
ultrasound, computed tomography (CT) and magnetic
resonance imaging (MRI) examination results, the pa-
tients were divided into three groups: 143 CHB patients,
including 81 men and 62 women, with a mean age of
43.2 ± 16.7 years, 86 LC patients, including 48 men and
38 women, with a mean age of 50.5 ± 18.5 years,and 79
HCC patients, including 49 men and 30 women, with a
mean age of 59.6 ± 17.3 years. All patients with diseases
affecting the heart, brain, and kidneys (among various
other vital organs) and those with other hepatotropic
virus infections were excluded. The control group
included 185 healthy examinees, including 105 men and
80 women, with a mean age of 48.6 ± 20.1 years.
Cell culture and transfection
HepG2 and HepG2.2.15 cells carrying the integrated
HBV genome [16] were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum. The cultures
were incubated in a cell incubator at 5% CO2 and 37°C.
HepG2 cells were seeded into 6- or 24-well cell plates
before transfection. When the cells reached approxi-
mately 80% confluency, 2 μg of plasmid DNA and 2 μL
of Lipofectamine 2000 (Invitrogen, U.S.A) were diluted
in 30 μL of Dulbecco’s Modified Eagle Medium
(DMEM), or 4 μg of plasmid DNA and 6 μL of Lipofec-
tamine 2000 reagent were diluted in 100 μL of RPMI-
1640. The reactions were allowed to proceed at room
temperature for 20 min. The prepared transfection
solution was added to the 24- or 6-well cell plates, and
the cells were further incubated in a CO2 incubator.
Reverse transcription polymerase chain reaction (RT-PCR)
assay
Total RNA was extracted from HepG2 and HepG2.2.15
cells using TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) [17]. The cDNA was synthesized using M-MLV
reverse transcription. PCR amplification for PLA2G2A
was verified using the following primers:
PLA2G2A sense: 5′ GCACTCAGTTATGGCTTC
T3′ and
PLA2G2A anti-sense: 5′ ATTGTAGGTCGTCTTGT
TTC 3′.
β-actin was amplified as a control. The PCR products
were checked using 1% agarose gel electrophoresis.
Luciferase assay
After transfection, HepG2 and HepG2.2.15 cells were
cultured for an additional 48 h. The cell supernatants
were removed, and the cells were harvested for lysis with
a cell lysis buffer. After lysis, 10 μL of cell lysate was
mixed with 100 μL of luciferase substrate, and the op-
tical density was measured using a luminometer. Each
sample was tested in triplicate.
Western blot assay
HepG2 cells were harvested and lysed, and then 30 μg of
protein from each sample was mixed with an equal
volume of 5X loading buffer, which was then boiled at
100°C for 5 min and separated using 12% SDS-PAGE gel
electrophoresis. The proteins were then transferred to a
nitrocellulose membrane and blocked with 5% skim milk
for 2 h. The membrane was incubated with the
PLA2G2A monoclonal antibody (1:1000) for 2 h. The
membrane was washed with PBST three times and then
incubated with anti-rabbit secondary antibody (Sigma,
1:5000) for 1 h. After four washes with PBST, the
membrane was subjected to color development using an
electrochemiluminescence (ECL) detection system
(Amersham Life Sciences).
Enzyme-linked immunosorbent assay (ELISA)
Approximately 2 mL of fasting venous blood was col-
lected from each subject. Serum levels of PLA2G2A
were measured using an ELISA kit (Cayman Chemical,
AnnArbour, MI, USA) following the manufacturer’s
instructions. Each sample was tested in triplicate.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) 16.0 statistical
package. The data are expressed as the mean ± standard
deviation x  sð Þ , and a logistic regression analysis
was performed adjusted for age. The differences among
the healthy controls and the patients with CHB, LC and
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HCC were assessed using one-way ANOVA, and a two




The demographic and clinical characteristics of the
subjects are shown in Table 1. There were no significant
differences in gender and body mass index (BMI) among
the 4 groups (P > 0.05). The subjects with more progres-
sive disease tended to be older. The aspartate transamin-
ase (AST) and alanine transaminase (ALT) levels were
higher in the CHB, LC, and HCC patients compared
with the healthy controls (p < 0.05), no significant differ-
ence existed among the CHB, LC, and HCC patients in
terms of the HBV DNA (P > 0.05).
Serum levels of PLA2G2A are elevated in HBV patients
Secreted PLA circulates in the blood stream and in
virtually every tissue in mammals. We then measured
the serum levels of PLA2G2A in healthy controls and in
CHB, LC, and HCC patients using an ELISA. The results
showed that the serum levels of PLA2G2A were 258.3 ±
20.3ng/dl, 329.0 ± 22.5ng/dl, 385.4 ± 29.3ng/dl, and
459.2 ± 38.6ng/dl in the healthy controls, CHB patients,
LC patients, and HCC patients, respectively. In the logis-
tic regression analyses adjusted by age, we found that
that compared with the healthy controls, the HBV pa-
tients had significantly higher serum levels of PLA2G2A
(P < 0.05), Furthermore, among the various groups of
patients, the serum levels of PLA2G2A consistently
increased with the progression of HBV diseases which is
in the order of HCC > LC > CHB patients (Fig. 1).
We further analyzed the relationship between the
serum levels of PLA2G2A and the clinical characteristics
in HCC patients. The results indicated that no signifi-
cant associations were found between serum PLA2G2A
levels and clinical factors including age and gender dis-
tribution (P > 0.05), whereas higher serum PLA2G2A
levels were associated with less frequent lymph node
metastasis and lower TNM stages (Table 2).
HBV increases PLA2G2A mRNA and protein expression
HepG2.2.15 cells were stably transfected with the
complete HBV genome, which expressed HBV RNA and
viral proteins and produced virus-like particles [18]. To
assess the effect of HBV on PLA2G2A expression, we
analyzed PLA2G2A mRNA and protein expression in
HepG2 and HepG2.2.15 cells using RT-PCR and western
blot assays. The results showed that HepG2.2.15 cells
expressed significantly higher levels of PLA2G2A mRNA
and protein than the HepG2 cells (Fig. 2a and b).
PLA2G2A gene promoter activity is triggered by pHBV1.3
PHBV1.3 is an infectious clone of HBV. After transfec-
tion with pHBV1.3, HepG2 cells can synthesize and
secrete HBV viral particles [9]. To investigate the
molecular mechanism by which HBV regulates
PLA2G2A expression, we co-transfected the HBV infec-
tious clone pHBV1.3 and the PLA2G2A gene promoter
pPLA2G2A-Luc into HepG2 cells, and pBlue-ks was
transfected as a control. Additionally, pPLA2G2A-Luc
was transfected into HepG2 and HepG2.2.15 cells
respectively. The results of a luciferase activity assay
showed that the PLA2G2A gene promoter activity was
significantly enhanced in the HepG2 cells after
transfection with pHBV1.3 (692.5 ± 28.8 RUL/μg pro-
tein, P < 0.05) compared with the control (279.6 ± 16.7
RUL/μg protein), and luciferase activity was much
higher in HepG2.2.15 cells (588.1 ± 21.3 RUL/μg
protein, P < 0.05) than in the HepG2 cells (243.2 ± 15.5
RUL/μg protein). This result indicated that HBV trig-
gered PLA2G2A gene promoter activity (Fig. 3a and b).
PHBV1.3 increases the PLA2G2A mRNA and protein
expression
We transfected pHBV1.3 into HepG2 cells and used an
empty vector transfection with pBlue-ks as a control.
Then, we analyzed the PLA2G2A mRNA and protein
expression using RT-PCR and western blot assays,
respectively. The results showed that compared with the
control, the PLA2G2A mRNA and protein expression
levels were increased in the HepG2 cells after transfec-
tion with pHBV1.3 (Fig. 4a and b).
Discussion
HBV is currently recognized as one of the main
causes of HCC. The mechanism by which HBV infec-
tion leads to HCC is complex, involving both the host
and viral factors [19]. For example, HBV can inacti-
vate the tumor suppressor gene P53 in the body,










Age (years) 48.6 ± 20.1 43.2 ± 16.7 50.5 ± 18.5 59.6 ± 17.3
Gender (M/F) 105/80 81/62 48/38 49/30
BMI(kg/m2) 26.3 ± 1.7 24.6 ± 1.5 25.2 ± 1.8 24.2 ± 1.6
ALT(IU/l) <30 183.5 ±
105.7
126.5 ± 98.4 65.7 ± 43.2
AST(IU/l) <30 207.4 ±
128.6
113.4 ± 86.5 83.2 ± 56.8
HBV DNA
(Lg copies/ml)
0 5.7 ± 2.6 5.5 ± 2.2 5.3 ± 2.4
Abbreviations: n number of the subjects, NS none sense, M male, F female, BMI
body mass index, ALT alkanine aminotransferase, AST
aspartate aminotransferase
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leading to uncontrolled cell proliferation and endan-
gering critical biological functions, such as DNA re-
pair and control [20]. Additionally, HBV viral
infection can induce a strong T cell immune response
in the host. However, this immune response kills he-
patocytes, which leads to inflammation and causes the
regeneration of many hepatocytes, inducing a carcino-
genic effect [21]. Moreover, HBV can regulate the ex-
pression of particular genes in the host, however,
these genes participate in the development and pro-
gression of HCC [7]. Our previous research showed
that HBV can increase the expression of collagen
triple helix repeat containing-1(CTHRC1), which is a
protein that plays a major role in promoting hepato-
cyte proliferation, migration, and invasion [22, 23].
In the present study, we found that HepG2.2.15 cells
expressed significantly higher levels of PLA2G2A mRNA
and protein than HepG2 cells. The serum levels of
PLA2G2A in HBV patients were significantly elevated
and associated with disease progression, lymph node
metastasis and TNM stage. We further demonstrated
that HBV increases PLA2G2A mRNA and protein ex-
pression by triggering the activity of its gene promoter.
HepG2.2.15 cells have a HBV stably integrated into
its genome and are capable of producing HBV-like vi-
ruses. The cells are mostly arrested in the G1 phase.
There is a reduction of filopodia, actin and ezrin in
HepG2.2.15, which makes them less invasive after im-
plantation in nude mice than the HepG2 parental
line, and the HepG2.2.15 implanted cells caused liver
necrosis, fatty liver, high cholesterol, degenerative
changes, and neutrophil infiltration [24]. This study
found that HepG2.2.15 cells had significantly in-
creased PLA2G2A levels compared with HepG2 cells.
PLA2G2A expression was elevated in primary gastric,
colon, and prostrate tumors and β-catenin–dependent
Wnt signaling is a major upstream regulator of
PLA2G2A expression [25]. Hepatitis B virus X (HBX)
protein upregulates β-catenin and the Wnt/β-catenin
pathway is frequently activated in HBV-induced HCC
[19, 26], which suggests that HBV might upregulate the
expression of PLA2G2A via the Wnt signaling pathways.
Recent studies showed that PLA2G2A is closely as-
sociated with the development and progression of
particular tumors [15, 27–29]. PLA2G2A can stimu-
late tumor cell growth, whereas the product of
PLA2G2A, arachidonic acid, leads to prostate tumor
cell proliferation and facilitates tumor angiogenesis
and metastasis. However, PLA2G2A expression was
decreased in metastatic and late-stage tumors and is
associated with prolonged survival and less frequent
metastasis in gastricadenocarcinoma [25]. In the
present study, we found that elevated PLA2G2A ex-
pression was associated with less frequent lymph
Fig. 1 Serum PLA2G2A levels in healthy controls and HBV patients. The serum PLA2G2A levels in the healthy controls and in CHB, LC, and HCC
patients were measured using an ELISA. *P < 0.05
Table 2 Association between PLA2G2A expression and clinical
characteristics in HCC patients
Characteristics Number Serum PLA2G2A levels(ng/dl) P value
Gender
Male 49 460.6 ± 40.3 0.472
Female 30 456.7 ± 36.5
Age (year)
≥ 60 53 458.5 ± 37.4 0.424
< 60 26 462.2 ± 41.7
Lymph node metastasis
Negative 47 482.6 ± 53.8 0.028
Positive 32 422.6 ± 31.3
TNM stages
I + II 28 491.7 ± 55.3 0.018
III + IV 51 415.8 ± 31.5
Abbreviations: n number of the subjects, TNM tumour node metastasis,
PLA2G2A phospholipase A2 group IIA
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node metastasis and lower TNM stages. However, this
study has certain limitations such as the small sample
size in the patient subgroups, and the evaluation of
the correlation of serum PLA2G2A levels with the
prognosis of HCC patients needs to be evaluated. In
addition, the detailed molecular mechanism of how
HBV induces the promoter activity of PLA2G2A
needs further investigation.
Conclusions
Taken together, for the first time, we demonstrated the
dynamic changes in PLA2G2A expression in the
Fig. 2 PLA2G2A mRNA and protein expression in HepG2 and HepG2.2.15 cells. a The relative mRNA levels of PLA2G2A in the HepG2 and HepG2.2.15
cells were measured using RT-PCR analysis. b PLA2G2A protein expression in HepG2 and HepG2.2.15 cells was measured using western blotting
Fig. 3 Effect of HBV on the activity of the PLA2G2A promoter. a HepG2 cells were co-transfected with pHBV1.3/pBlue-ks and the PLA2G2A promoter
pPLA2G2A-Luc plasmid, and then luciferase activity was measured. b HepG2 and HepG2.2.15 cells were transfected with PLA2G2A promoter
pPLA2G2A-Luc plasmid, and then luciferase activity was measured. *P < 0.05
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progression of HBV infection ranging from CHB, LC to
HCC. Therefore, measuring the serum levels of
PLA2G2A in HBV patients may provide a new
biomarker for the diagnosis of progressive liver diseases
during chronic HBV infection.
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